Meridian Bioscience (Nasdaq: VIVO) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q3), Meridian Bioscience met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. GAAP earnings per share increased.

Gross margins contracted, operating margins expanded, net margins expanded.

Revenue details
 Meridian Bioscience recorded revenue of $47.1 million. The nine analysts polled by S&P Capital IQ wanted to see net sales of $47.0 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $42.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.24. The 12 earnings estimates compiled by S&P Capital IQ predicted $0.22 per share. GAAP EPS of $0.24 for Q3 were 14% higher than the prior-year quarter's $0.21 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 65.0%, 60 basis points worse than the prior-year quarter. Operating margin was 33.3%, 250 basis points better than the prior-year quarter. Net margin was 21.6%, 120 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $48.8 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $188.9 million. The average EPS estimate is $0.89.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 455 members out of 465 rating the stock outperform, and 10 members rating it underperform. Among 112 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 110 give Meridian Bioscience a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $21.22.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Meridian Bioscience. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.